CAC
CYTK icon

Cowen and Company’s Cytokinetics CYTK Stock Holding History

Cowen and Company’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,000
Closed -$16K – 95
2024
Q3 		$16K Hold
20,000
– – ﹤0.01% 455
2024
Q2 		$58K Sell
20,000
-490,000
-96% -$29.6M ﹤0.01% 306
2024
Q1 		$13.1M Buy
+510,000
New +$39.4M 0.51% 21
2020
Q3 		– Sell
-20,400
Closed -$174K – 446
2020
Q2 		$174K Buy
+20,400
New +$383K 0.03% 208

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Cowen and Company's CYTK Position: Q1 2024 in Review

Cowen and Company sold out of Cytokinetics (CYTK) in Q1 2024, closing a stake of 56,828 shares — an estimated $4.4M sold.

Cowen and Company first reported a position in CYTK in Q4 2023 and held it in 1 quarter. The position peaked at $4.74M in Q4 2023. 390 funds tracked by Wall St. Rank hold CYTK as of Q1 2024.

  • Cowen and Company reported no remaining Cytokinetics position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 56,828 Cytokinetics shares in Q1 2024, an estimated $4.4M.
  • Cowen and Company first reported a position in Cytokinetics in Q4 2023 and held it in 1 quarter.
  • Cowen and Company's Cytokinetics position peaked at $4.74M in Q4 2023.
  • 390 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.